| INTRODUCTION
The treatment of allergic rhinitis (AR) is complex as many drugs are available in oral and/or topical formulations. Many guidelines for AR are evidence-based and have led to a better understanding and management of AR. However, guidelines are mostly based on randomized controlled trials (RCTs), typically undertaken on highly selected populations, often with limited/unclear generalizability to routine care contexts. [1] [2] [3] Large observational implementation studies are needed to triangulate RCT as they reflect "real world" every day use and practice more closely than RCTs in terms of the heterogeneous patient populations included, and the variety of medical interventions assessed. 4 In RCTs, each subject is randomly assigned to a treatment or control group, whereas observational studies examine the possible effect of a treatment on subjects where the investigator has no control over the experiment and cannot randomize subject allocation. 5 However, observational studies provide clinically relevant information in addition to RCTs.
MACVIA-ARIA Sentinel NetworK (MASK)-rhinitis (MASK for AR),
an information and communications technology (ICT) system centered around the patient, [6] [7] [8] 
| ME TH ODS

| Design of the study
This prospective observational study of a mobile applicationthe Allergy Diary-was used to assess self-reported medication use.
The objectives of this study were (i) to report the median VAS global-measured values depending on the treatment received, (ii) to undertake a sensitivity analysis by comparing the results for 1 day of treatment, the full data set, and a restricted data set (ie, 2016 and the first 2 weeks of treatment), (iii 
| Setting
Users from 15 countries filled in the Allergy Diary (Table 1) .
| Allergy Diary
Geolocalized users assess their daily symptom control using the touch screen functionality on their smart phone to click on 5 consecutive VAS (ie, general, nasal and ocular symptoms, asthma, and work) ( Figure S1 ). Users input their daily medications using a scroll list which contains all country-specific over the counter (OTC) and prescribed medications available ( Figure S2 ). The list has been populated using IMS data.
| Ethics
The Allergy Diary is CE1 registered, but it was not considered by the Ethical Committee of the Cologne Hospital of the Medicines and Healthcare products Regulatory Agency (MHRA-GOV.UK) as a medical device given that it does not provide any recommendations concerning treatment or diagnosis. The terms of use were translated into all languages and customized according to the legislation of each country, allowing the use of the results for research purposes. The example of the UK terms of use has been provided in a previous paper.
11
The data were anonymized except for the geolocalized data which are never totally anonymous. This issue was carefully considered in the first paper on the Allergy Diary.
An Independent Review Board approval was not required.
| Outcomes
In this study, initial characteristics (Table S1) , 11 4 VAS measurements (VAS-global measured, VAS-nasal, VAS-ocular, and VAS-work, Table S2 ) and a calculated VAS-global-calculated score (VASnasal + VAS-ocular divided by 2) were considered. The VAS-asthma was not analyzed as there was a change in the question on June 1, 2016. VAS levels range from zero (not at all bothersome) to 100 (very bothersome). Independency of VAS questions was previously assessed using the Bland and Altman regression analysis. 13, 14 Days reported by users included days with or without treatment.
This study is another Allergy Diary study. None of the data used in the first paper 11 were used in this study. Data of the second paper were used, but the analysis was totally different as we analyzed medication effects whereas in the former paper the focus was on work productivity. 
| Selection of medications
The International Nonproprietary Names (INNs) classification was used for drug nomenclature. 15 Monotherapy was defined as days when only one single medication for rhinitis was taken. Polymedication (comedication) was defined as days with 2 or more medications for rhinitis. Asthma medications were not considered in polymedica- 
| Biases
There are potential measurement biases when using apps as the information collected is usually restricted. The self-reported nature of the data represents another bias inherent to App usage. A bias might be introduced because app users may be a selected subset, and are therefore not fully representative of all patients with rhinitis.
Finally, it is not known whether users fill in their information before or after treatment for a given day.
| Size of the study
In this exploratory pilot study, all registered users between May 21, 2015, and November 8, 2016, were included to obtain the best possible estimates for the specified time window.
| Statistical methods
A non-Gaussian distribution was found for the data. Nonparametric tests and medians (and percentiles) were used.
Some users reported VAS scores more than once a day. Before analysis, we proposed that if the same treatment was reported and the daily variation was under 30%, the highest VAS score would be used as previously. 13 In the full data set, there were 631 days with multiple values, and of these, only 133 (1.4%) had a variation >30%.
We decided that this number was not sufficient enough to impact the results and we used the highest value for the day.
| Analysis of the data
The study was not a longitudinal study because (i) there was an insufficient number of users reporting data over a period of 5 days Although there may be causal inferences, we used cross-sectional data for days of treatment. We analyzed the full data set and performed the following sensitivity analyses: (i) A restricted analysis Data from Australia, Brazil, Canada, Mexico, and Switzerland were excluded due to the low number of users (enrollment started in October 2016).
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(REST) was performed on up to the first 15 days of treatment in users who initiated their study in 2016, and (ii) the first day of reporting was analyzed as there was a higher level of VAS on day 1 than on the other days and there were more users with a single day than with multiple days.
| Medications used and adherence to treatment
All users were investigated for 2015 and 2016, and the number of days of reporting VAS levels was assessed. We then studied 2016
and examined the adherence to treatment in users who reported 5-7, 8-15 and >16 days. In the latter group, only the first 30 days were investigated. Adherent users were those reporting ≥80% consecutive days and ≥80% days with the same treatment. Non-adherent users were those reporting <80% days with the same treatment.
Discontinuous users were those reporting <80% consecutive days and ≥80% days with same treatment. We then checked the number of medications reported during the period of examination.
| Control of the disease
Using the full data set and REST, we studied median VAS levels for medications reported for at least 1000 days and for days without medications. We used the global-measured VAS as a primary endpoint and the other VAS measures (nose, eyes, work) as secondary endpoints. 12 As this was a pilot study, only the primary endpoint was analyzed using the Kruskal-Wallis test with Dunn's post hoc analysis.
| Prescribed medications
We then focussed on the 3 medications always prescribed, that is, Table 1) .
Among the 17 091 VAS days, all users filled in VAS-nasal and VAS-ocular, but 436 days were not filled in for VAS-global measured ("No" to Q1). 
| Treatments and adherence
| Overall results
Data obtained were extremely consistent for different VAS measurements (global measured, nose, eyes, and work) or different analyses (full data set and restricted data set across all outcomes) ( Table 3 ). In the full data set, VAS scores were greater on days with treatment 
| Single therapy and comedication
The results were extremely consistent as, for all medications apart from desloratadine, days under monotherapy (or MP-AzeFlu) had significantly lower VAS-global-measured median levels than days with comedication (Table 4) .
| Prescribed medications
Only 3 medications containing INCS were exclusively prescribed. MF was OTC in some countries, but the users were low in number and therefore not included in the analysis. There were major differences between treatments in the percentage of mono-and comedication including OAH used. MP-AzeFlu was used more often alone (64-68%) than FF (32-37%) or MF (38-46%), and these trends were found in day 1 and persisted across the study (Figure 2 ).
The results for the 3 INCS-containing medications as rhinitis monotherapy, treatment with an oral H1-antihistamine (OAH), or any other medication for rhinitis (polymedication) are presented in The control of days differs between no (best control), single, or multiple treatments (worst control).
| Strengths and limitations
Smart devices and Internet-based applications are already used in rhinitis, [16] [17] [18] [19] [20] [21] Data obtained were extremely consistent for different VAS measurements (global measured, nose, eyes, and work) or different analyses (full data set, day 1 and REST). In a previous paper, we showed that there were strong to very strong correlations between the overall control of rhinitis and work VAS. 13 In the present study, the definition of having rhinitis is purely user dependent. As the definition of rhinitis is not clear to the users other conditions, such as chronic rhinosinusitis or nasal septal deviation, could have been considered as AR. Although the App does not allow the assessment of all the analyses proposed to differentiate between these diseases, sneezers and blockers will be differentiated in the next analysis as previously done. 11 However, this was not done in the present study because (i) there was an insufficient number of users, and (ii) in this pilot analysis, we wanted to mimic a real-life study. From our experience in GPs, differentiation between allergic and nonallergic rhinitis is difficult and most GPs do not attempt to make any differences between nasal symptoms. 1, 22, 23 The study as already mentioned has no pretentions of reflecting the general population because (i) only one shot was taken into account, (ii) people using an App are not representative of the general population, and (iii) the users reported few days. However, the sample size is important, and according to the law of large numbers, the characteristics of a random sample approach the statistical characteristics of the population from which the sample is extracted when the sample size increases.
Adherence is difficult to analyze without a real assessment by electronic pill counters or inhalers. These do not exist for nasal a-c: Kruskal-Wallis P < .0001, Bonferroni-Dunn's post hoc analysis: a/b: NS, a/c: P < .05, b/c: P < .05.
d-h: Kruskal-Wallis P < .0001, Bonferroni-Dunn's post hoc analysis.
products or are currently being tested. Questionnaires can be used, but it appears that real-life data are more appropriate. However, it
should be emphasized that users may not report all medications used.
Longitudinal data capture was very challenging because treatment trajectories are specific for almost each user, and most users have gaps in treatment days when they are well-controlled, hence the focus on a cross-sectional analysis on days of treatment.
| Interpretation of the results and generalizability
The real-world assessment of the Allergy Diary using VAS allows N  1039  589  406  846  625  743  610  492  622  671   Minimum  0  0  0  0  0  0  0  0  0  0   Maximum  100  99  100  100  100  100  100  100  100 Statistical analysis by Kruskal-Wallis test (P < .0001) and Dunn' post hoc analysis. P < .05: significant for full data set and REST, P < .05: significant for full data set only. Users with comedication other than OAH were not included due to their low number.
more objective estimation of AR treatments than patients' comments as (i) it is known that AR is a highly variable disease, and control varies widely between days in relation to allergen exposure,
(ii) patients are not always adherent with their treatment, (iii) patients often stop treatment when they feel better (as found by the study but not shown), and (iv) patients increase their treatment when uncontrolled.
VAS scores were greater on treatment days than on days without treatment, suggesting that users reporting no treatment had milder disease than those who were occasionally treated. However, median VAS levels on days without treatment were similar in users who never reported any medication use and in those who were occasionally treated. Days without treatment were better controlled than days with treatment and days with a single treatment were better controlled than days with multiple treatments. These data suggest that, in real life, patients treat themselves when they suffer from symptoms and stop their treatment when they are controlled.
This accords with previous data. 24, 25 This study, using objective data, confirmed that adherence is poor. Most patients with rhinitis may have mild and/or intermittent disease that does not need a regular treatment to achieve control. 31 or components using the same formulation. 32 However, observational studies comparing prescribed medications containing INCS are not available. In the present study, a clear difference was found between medications. Disease control assessed by VAS was similar in users who reported a single treatment for the 3 medications and was similarly increased in those with comedication. However, a major difference is that around one-third of MP-AzeFlu received the treatment without comedication whereas FF or MF users required comedication in 31%-46%. Although this is a pilot study, over 1000 days of treatment were reported for each medication. A bias may, however, be confounding by indication.
| CONCLUSIONS
This observational study shows highly consistent results between different outcomes (VAS levels), days of treatment and medications.
It appears possible to use this approach to better tailor treatments to individuals. 
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